Unum therapeutics inc. (UMRX)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17
Assets
Current assets:
Cash and cash equivalents

29,604

37,424

45,882

55,863

59,114

55,671

49,296

46,732

25,704

28,270

Marketable securities

-

-

0

0

7,989

22,923

37,824

47,715

-

12,691

Marketable securities

-

-

-

-

-

-

-

-

6,696

-

Accounts receivable

-

2,000

880

1,492

2,040

1,668

1,419

1,202

1,601

830

Prepaid expenses and other current assets

1,581

1,167

1,216

1,243

757

740

960

1,412

1,176

513

Restricted cash

-

-

-

-

-

-

-

50

50

75

Total current assets

31,185

40,591

47,978

58,598

69,900

81,002

89,499

97,111

35,227

42,379

Operating lease, right-of-use asset

4,929

5,285

5,634

5,977

6,316

-

-

-

-

-

Property and equipment, net

1,570

1,865

2,170

2,632

2,963

3,251

3,613

3,938

3,902

4,108

Restricted cash

1,255

1,255

1,255

1,255

1,255

1,255

1,255

1,255

1,255

1,255

Deferred offering costs

-

-

-

-

-

-

-

-

2,612

1,373

Other assets

-

427

847

846

846

419

419

419

419

-

Total assets

38,939

49,423

57,884

69,308

81,280

85,927

94,786

102,723

43,415

49,115

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable

628

3,183

1,594

1,660

1,836

1,519

803

1,664

3,083

1,346

Accrued expenses and other current liabilities

6,123

7,131

6,538

5,929

6,067

5,477

-

-

-

2,953

Operating lease liability

1,658

1,619

1,581

1,543

1,507

-

-

-

-

-

Deferred revenue

841

1,315

14,717

15,175

16,935

17,949

-

-

-

6,891

Accrued expenses and other current liabilities

-

-

-

-

-

-

5,495

2,787

2,358

-

Deferred revenue

-

-

-

-

-

-

20,086

20,363

17,519

-

Total current liabilities

9,250

13,248

24,430

24,307

26,345

24,945

26,384

24,814

22,960

11,190

Deferred rent

-

-

-

-

-

748

871

888

902

906

Operating lease liability, net of current portion

3,987

4,413

4,831

5,243

5,645

-

-

-

-

-

Deferred revenue, net of current portion

-

-

-

-

-

-

-

-

-

8,714

Deferred revenue, net of current portion

-

-

-

-

-

-

-

346

3,655

-

Total liabilities

13,237

17,661

29,261

29,550

31,990

25,693

27,255

26,048

27,517

20,810

Commitments and contingencies (Note 8)

-

-

-

-

-

-

0

0

0

-

Redeemable convertible preferred stock (Series A and B), $0.001 par value; no shares and 20,791,407 shares authorized at December 31, 2018 and 2017, respectively; no shares and 20,771,850 shares issued and outstanding at December 31, 2018 and 2017, respectively

-

-

-

-

-

-

-

-

77,167

77,151

Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding

-

-

-

-

-

-

0

0

-

-

Common stock, $0.001 par value; 150,000,000 shares authorized; 30,821,892 shares and 30,663,054 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively

31

30

30

30

30

30

30

30

10

10

Additional paid-in capital

155,657

155,624

154,782

153,994

153,012

152,275

150,978

149,943

2,990

2,499

Accumulated other comprehensive loss

-

-

-

-

-2

-12

-24

-13

-7

-16

Accumulated deficit

-129,986

-123,892

-126,189

-114,266

-103,750

-92,059

-83,453

-73,285

-64,262

-51,339

Total stockholders’ equity

25,702

31,762

28,623

39,758

49,290

60,234

67,531

76,675

-61,269

-48,846

Total liabilities and stockholders' equity

38,939

49,423

57,884

69,308

81,280

85,927

94,786

102,723

43,415

49,115